Apotex Dodges Extra Damages In Prilosec Patent Suit
A federal judge has ruled that Apotex Corp. did not willfully violate two patents held by AstraZeneca AB when it began selling a generic version of Prilosec in 2003, precluding AstraZeneca...To view the full article, register now.
Already a subscriber? Click here to view full article